Sometimes his application is rejected within 15 minutes of submission, he said.
并且，12个月内Infigratinib治疗患者身高平均增长2.51厘米，Vosoritide仅为1.41厘米。根据公司的表述，Infigratinib在3-8岁儿童的年化生长速度是迄今为止研究的最广泛年龄范围内，是改善效果最高和最显著的。
，这一点在旺商聊官方下载中也有详细论述
圖像來源，Getty Images
"It's not bad, but I also think there's a reason why it's not necessarily blowing up in a massive way, because I don't necessarily think it's original," she says.